Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,090.00
+40.00 (0.66%)
Feb 20, 2026, 3:30 PM KST

Kyongbo Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2,5784,1284,4776,3484,29011,439
Short-Term Investments
1,8302,000870870-9,543
Cash & Short-Term Investments
4,4086,1285,3477,2184,29020,983
Cash Growth
88.79%14.60%-25.92%68.25%-79.55%209.99%
Accounts Receivable
59,92151,62456,16050,20246,90650,501
Other Receivables
480.74686.7697.94597.63988.692,226
Receivables
60,40252,31156,85850,79947,89552,727
Inventory
90,06690,58570,66457,44357,67062,173
Prepaid Expenses
372.661,3111,610115.43913.71,439
Other Current Assets
1,6831,6061,423749.74397.53870.73
Total Current Assets
156,932151,941135,902116,326111,166138,192
Property, Plant & Equipment
123,91599,85296,07393,91995,67790,100
Long-Term Investments
14,19711,12113,67611,93514,38411,828
Other Intangible Assets
4,0154,0083,6413,2213,3553,091
Long-Term Deferred Tax Assets
13,19013,56513,20311,95110,1797,609
Other Long-Term Assets
4,2393,3993,8103,1942,2182,420
Total Assets
316,488283,887266,305240,545236,979253,239
Accounts Payable
13,50014,95122,77514,74216,40414,293
Accrued Expenses
3,6143,5373,3982,7932,5532,538
Short-Term Debt
122,28389,27173,09563,90055,23461,218
Current Portion of Long-Term Debt
-4590909090
Current Portion of Leases
1,0701,0741,078280.59787.02765.11
Current Income Taxes Payable
10.9786.85118.34166.28-976.16
Other Current Liabilities
25,36323,69517,70713,59613,74613,883
Total Current Liabilities
165,841132,660118,26195,56988,81493,764
Long-Term Debt
--45135225315
Long-Term Leases
536.81,0431,629106.58250.75876.89
Pension & Post-Retirement Benefits
2,2421,482--927.431,593
Other Long-Term Liabilities
2,5892,5481,9881,0301,061634.15
Total Liabilities
171,209137,733121,92496,84191,27897,182
Common Stock
11,95311,95311,95311,95311,95311,953
Additional Paid-In Capital
40,06740,06740,06740,06740,06740,067
Retained Earnings
97,62598,33396,03394,69594,587104,207
Comprehensive Income & Other
-4,366-4,199-3,672-3,012-907.41-171.32
Shareholders' Equity
145,279146,154144,381143,704145,701156,057
Total Liabilities & Equity
316,488283,887266,305240,545236,979253,239
Total Debt
123,89091,43375,93664,51256,58763,265
Net Cash (Debt)
-119,481-85,305-70,589-57,294-52,296-42,283
Net Cash Per Share
-4991.18-3568.22-2942.80-2439.66-2190.88-1766.95
Filing Date Shares Outstanding
23.9123.9123.9123.9123.9123.91
Total Common Shares Outstanding
23.9123.9123.9123.9123.9123.91
Working Capital
-8,90919,28117,64120,75722,35244,429
Book Value Per Share
6076.886113.486039.336011.006094.526527.70
Tangible Book Value
141,264142,146140,741140,483142,346152,966
Tangible Book Value Per Share
5908.935945.845887.055876.265954.196398.43
Land
30,14630,14628,63327,56923,87419,510
Buildings
92,48782,77981,33679,34176,85173,165
Machinery
133,001125,238119,358113,325111,02297,341
Construction In Progress
21,7427,9591,8561,4441,7296,698
Source: S&P Global Market Intelligence. Standard template. Financial Sources.